Objective: To evaluate long-term safety/tolerability and seizure outcomes in patients with focal seizures treated with adjunctive perampanel in the open-label extension (OLEx) Study 307 (ClinicalTrials.gov identifier: NCT00735397). Methods: Patients could enter the OLEx after completing one of the doubleblind, phase III studies. Safety/tolerability and seizure outcomes (median percent reduction in seizure frequency per 28 days, and 50% responder and seizure freedom rates) were analyzed during the OLEx in cohorts with the same minimum perampanel exposure for all focal seizures and secondarily generalized seizures (SGS). An additional sensitivity analysis accounted for early dropouts from the OLEx. Results: Of 1480 patients randomized across the double-blind studies, 1218 enrolled in the OLEx. The majority of patients (65.4%-80.9%) received a last daily dose of perampanel 12 mg and completed long-term assessment on the same, or one fewer, concomitant antiepileptic drug compared with baseline. The long-term safety/tolerability profile was consistent with the double-blind studies.
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patients, respectively, attained freedom from SGS. Median percent seizure reductions per 28 days were similar when early dropouts were accounted for. Significance: Long-term (≤4 years) adjunctive perampanel treatment did not raise new safety/tolerability signals and was associated with markedly improved seizure control, particularly in patients with SGS at baseline.
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| INTRODUCTION
Perampanel is approved in the United States, European Union, and many other countries for adjunctive treatment of focal (partial-onset) seizures, with or without secondarily generalized seizures (SGS), and primary generalized tonicclonic seizures in patients with epilepsy ≥12 years of age.
1,2 Perampanel is also approved for monotherapy use for focal seizures in the United States and Philippines, and for conversion to monotherapy in Switzerland in patients with epilepsy ≥12 years of age. In 3 double-blind, phase III studies in patients with focal seizures receiving 1 to 3 concomitant antiepileptic drugs (AEDs), perampanel was shown to be superior to placebo in reducing seizure frequency during the 19-week assessment period. [3] [4] [5] For patients who completed one of the double-blind, phase III studies and entered an open-label extension (OLEx) study, a sustained improvement in seizure frequency associated with good tolerability was observed during 2 years of perampanel exposure. 6 After 2 years of followup, the median percent reduction in seizure frequency per 28 days was 60% relative to the pre-perampanel baseline, and the 50% responder rate (the proportion of patients with a ≥50% reduction in seizure frequency per 28 days relative to baseline) was 58%. In patients with SGS at baseline, up to 90% reduction in seizure frequency was observed. 6 Currently, over 100 000 patients globally have been treated with perampanel (data on file, Eisai Inc., NJ, USA). The present study was designed to investigate the tolerability of adjunctive perampanel beyond 2 years of treatment and to evaluate seizure outcomes in patients with focal seizures, with or without SGS, treated with once-daily adjunctive perampanel for ≥3 (n = 436) or ≥4 (n = 78) years while in the OLEx study.
| METHODS

| Participants and study design
The designs of the 3 adjunctive-therapy, double-blind, phase III studies (Study 304, NCT00699972; Study 305, NCT00699582; and Study 306, NCT00700310) have been described in detail elsewhere. [3] [4] [5] Patients (aged ≥12 years) with focal seizures, with or without SGS, who completed 1 of the 3 double-blind, phase III studies were eligible to enter the OLEx study (Study 307; ClinicalTrials.gov identifier: NCT00735397). 6 The OLEx study consisted of a 16-week, blinded conversion period and a long-term, open-label maintenance period (up to 256 weeks). Patients entered the conversion period on the same dose of perampanel they had achieved at the end of the double-blind treatment phase. For patients who had received placebo or perampanel <12 mg/day during the double-blind studies, the dose of perampanel was uptitrated (in 2-mg increments biweekly) to 12 mg/day (or the maximum tolerated dose). Perampanel 2 mg was the starting dose during conversion for those previously on placebo. During the OLEx maintenance period, patients remained on the maximum tolerated dose of perampanel achieved during the blinded conversion period, unless further dose adjustment for tolerability and/or seizure control was necessary. Adjustment of dose, discontinuation, or change of concomitant AEDs was
Key points
• The long-term safety/tolerability profile of perampanel was similar to that observed during the double-blind, phase III studies
• Long-term adjunctive perampanel treatment for up to 4 years was associated with sustained improvement in seizure control
• Most substantial improvement occurred for secondarily generalized seizures (SGS) in patients with SGS at baseline
• Across cohorts defined by perampanel exposure duration, 14.3% to 53.6% of patients became free of SGS
• Across cohorts with 1-4 years of exposure, 0.0% to 12.8% of patients were free from all seizures during perampanel treatment permitted at the investigator's discretion. 7 However, the majority of patients (65.4%-80.9%) remained on the same concomitant AEDs taken at baseline or on 1 fewer AED compared with baseline. Patients remained in the study unless they withdrew due to adverse events (AEs), patient choice, or inadequate therapeutic effect. The study was terminated in 2012, following perampanel's marketing approval by the European Medicines Agency (EMA). Therefore, patients could also have discontinued the study for an administrative reason, as a result of study closure, or the commercial availability of perampanel in their country.
All patients provided written, informed consent prior to participating in the study. The study protocol was reviewed by national regulatory authorities and independent ethics committees/institutional review boards. 6 2.2 | Safety/tolerability and seizure outcomes Safety/tolerability measures included the following: incidence rates of treatment-emergent adverse events (TEAEs); treatment-emergent serious adverse events (SAEs); discontinuations due to AEs; and exposure-adjusted event rate of TEAEs (defined as the number of TEAEs that occurred per patient year of treatment). The exposure-adjusted event rate analysis was performed to allow a more accurate comparison of TEAEs to be made across varying periods of perampanel exposure. AEs were considered treatment-emergent if they began on or after the day of the first dose of perampanel, occurred up to 30 days after the last dose, or began before perampanel exposure but increased in severity during treatment. 6 Seizure outcome data included the following: median percent change in seizure frequency per 28 days relative to pre-perampanel baseline; 50% responder rate per year (ie, the previous 12 months) relative to pre-perampanel baseline; and seizure freedom rate per year. Seizure outcome data were collected for up to 4 years and analyzed in cohorts of patients with the same minimum duration of perampanel exposure. 6 
| Data analysis
Data were summarized with descriptive statistics. The Safety Analysis Set included all patients who provided written, informed consent for the OLEx, received at least 1 dose of perampanel in the OLEx, and had at least 1 postdose safety/tolerability assessment in the OLEx. The Intentto-Treat (ITT) Analysis Set included all patients who provided informed consent for the OLEx, received at least 1 dose of perampanel in the OLEx, and had valid seizure data during the perampanel treatment duration. 6 An additional sensitivity analysis was conducted to include patients who withdrew from the study at all time points. The last observation carried forward approach (ie, the last year of treatment was carried forward to later time points) was used for all patients, regardless of whether they withdrew because of investigator or patient choice, or for administrative reasons.
3 | RESULTS 3.1 | Patient disposition, exposure, and retention rates
Of 1480 patients randomized across the 3 double-blind, phase III studies, 1218 enrolled in the OLEx study. Of these, 380 were previously randomized to placebo and 838 were randomized to perampanel in the double-blind studies. The Safety Analysis Set included 1216 patients, and the ITT Analysis Set included 1217 patients. In the Safety Analysis Set, duration of perampanel treatment was at least 1 year for 894 patients (73.5%), at least 2 years for 681 patients (56.0%), at least 3 years for 436 patients (35.9%), and at least 4 years for 78 patients (6.4%). Baseline demographics (Table S1 ) were similar across all cohorts with regard to mean age (30-34 years), sex (50%-67% male), and mean body weight (69.5-69.9 kg).
The majority of patients were taking 2 or 3 concomitant AEDs at baseline (Table S1 ). During the OLEx, concomitant AED treatment could be modified at the investigator's discretion. Table S2 shows the shift in the number of AEDs from baseline to the end of treatment for patients with at least 1, 2, 3, and 4 years of perampanel exposure. The majority of patients remained on the same AEDs at baseline and at the end of treatment: 64.1%, 63.9%, 63.5%, and 43.6% for patients with at least 1, 2, 3, or 4 years of perampanel exposure, respectively; or took 1 fewer AED at the end of treatment compared with baseline: 16.8%, 16.2%, 15.4%, and 21.8% for patients with at least 1, 2, 3, or 4 years of perampanel exposure, respectively. The addition of another AED during the entire OLEx study was recorded in 20.8%, 21.7%, 23.6%, and 37.2% of patients with at least 1, 2, 3, or 4 years of perampanel exposure, respectively. Four patients (0.9%) with at least 3 years of perampanel exposure and 1 patient (1.3%) with at least 4 years of perampanel exposure were not receiving any concomitant AEDs at the end of treatment.
The mean AE standard deviation (SD) daily dose of perampanel across the entire OLEx was 10.1 AE 2.3 mg/day. The average daily dose was similar for all patients, regardless of their minimum perampanel exposure (range of average doses for patients with at least 1 to at least 4 years of perampanel exposure: 10.1-10.6 mg/day). The last daily dose was 12 mg for 59.2%, 62.1%, 64.9%, and 62.8% of patients with at least 1, 2, 3, or 4 years of perampanel exposure, respectively. The 1-, 2-, 3-, and 4-year retention rates were 73.5% (894/1216), 56.4% (681/1207), 46.2% (436/ 944), and 39.0% (78/200), respectively ( Table 1) . The majority of patients completed the safety/tolerability study or were categorized as discontinuing the study for "administrative" reasons (ie, result of study closure or the commercial availability of perampanel in their country). Figure 1 shows the estimated probability of time to discontinuation; patients who discontinued for administrative reasons were included as censored observations. The next most common reason for discontinuing was patient choice. Most discontinuations for inadequate therapeutic effect and AEs occurred during the first year of therapy (Table 1) .
| Long-term safety/tolerability outcomes in the overall population
During the entire perampanel exposure, at least 1 TEAE was reported for 92.9% (1130/1216) of patients. Of the patients who continued into the OLEx study, TEAEs were reported in 64.7% (787/1216) of patients during the titration period (6 weeks for the double-blind study and 16-week conversion period during the OLEx) and in 98.4% (1002/1018) of patients during the maintenance period. Patients with at least 1, 2, 3, or 4 years of perampanel exposure had a similar incidence of TEAEs (approximately 93%; Table 2 ). Most TEAEs were mild (25.8%) or moderate (45.4%), and classified by investigators as possibly (42.0%) or probably related (41.6%) to treatment. TEAEs reported in ≥10% of patients were dizziness, somnolence, headache, fatigue, weight increase, irritability, and nasopharyngitis (Table 2) , which occurred at similar rates in each exposure cohort. In addition to these TEAEs, fall, nausea, and convulsion were also among the top 10 TEAEs that occurred during perampanel exposure, with incidence rates of 9.7%, 9.6%, and 9.3%, respectively. The overall exposure-adjusted rates (number of TEAEs that occurred per patient year of treatment) for these most common TEAEs during the OLEx were the following: dizziness, 0.41 (n = 407); somnolence, 0.46 (n = 452); headache, 0.52 (n = 507); fatigue, 0.29 (n = 282); weight increase, 0.21 (n = 204); irritability, 0.17 (n = 167); and nasopharyngitis, 0.24 (n = 239).
Through 4 years of perampanel exposure, treatmentemergent SAEs, including fatal events, were reported in 288 patients (23.7%) in the Safety Analysis Set, with the most common being related to epilepsy. Overall exposureadjusted rates (number of TEAEs that occurred per patient year of treatment) for the most common SAEs (≥10 patients) were 0.04 for convulsion (n = 43); 0.02 for status epilepticus (n = 16) and epilepsy (n = 15); and 0.01 for aggression (n = 14), pneumonia (n = 13), and head injury (n = 12). SAEs were reported in 25.1%, 25.6%, 27.1%, and 26.9% of patients with at least 1, 2, 3, or 4 years of perampanel exposure, respectively. A total of 11 deaths were recorded, of which 2 were classified as a sudden unexpected death in epilepsy (SUDEP) and 2 separate ones as a result of convulsion. Other causes of death included respiratory failure, chronic obstructive pulmonary disease, colon cancer, cerebral hemorrhage, subdural hemorrhage, traffic accident, and cardiac arrest. Ten deaths were considered by the investigator as not related to study treatment; 1 death due to convulsions in an adolescent patient was assessed as possibly related to study treatment. None of the deaths were a result of suicide or psychiatric and behavioral adverse reactions.
TEAEs resulting in discontinuation from the study or from perampanel treatment occurred in 231 patients (19%) in the Safety Analysis Set through the 4 years of exposure to perampanel. Dizziness (n = 50, 4.1%), irritability (n = 15, 1.2%), and fatigue (n = 13, 1.1%) were the only TEAEs that resulted in discontinuation of ≥1% of patients. Discontinuation due to a SAE (other than death) occurred in 57 patients (4.7%). SAEs leading to discontinuation in ≥0.25% of patients included aggression (n = 7, 0.58%), convulsion (n = 5, 0.41%), epilepsy (n = 4, 0.33%), suicidal ideation (n = 4, 0.33%), acute F I G U R E 1 Kaplan-Meier plot of estimated time to discontinuation. Patients who discontinued for reasons other than administrative reasons are included as events; patients who discontinued due to administrative reasons or who completed the study are included as censored observations (represented by the circles in this plot). This plot is based on the assumption that censored patients (ie, patients who discontinued for administrative reasons or completed the study) are similar to those patients who were followed until the end of treatment T A B L E 2 TEAEs during perampanel exposure in ≥10% of the total Safety Analysis Set by cohort Percentages are based on the total number of patients in the relevant treatment group. A patient with 2 or more TEAEs in the same preferred term is counted only once for that preferred term. For patients who received perampanel in the preceding double-blind study, perampanel exposure consisted of the double-blind plus the OLEx phases. For patients who received placebo in the preceding double-blind study, perampanel exposure consisted of the OLEx phase only.
psychosis (n = 3, 0.25%), and status epilepticus (n = 3, 0.25%). Table S3 shows the overall exposure-adjusted event rate of TEAEs (number of TEAEs that occurred per patient year of treatment) for patients with at least 1, 2, 3, or 4 years of perampanel exposure. Dizziness was the most common TEAE, with an overall exposure-adjusted rate of 44.6, 38.8, 38.1, and 34.2 for patients with at least 1, 2, 3, or 4 years of perampanel exposure, respectively. The most common neuropsychiatric disorders were irritability, insomnia, and depression, which occurred in approximately 14%, 8%, and 8% of patients, respectively, across cohorts. The proportion of patients experiencing neuropsychiatric disorders was generally consistent in all patient cohorts. Abnormal weight gain was also consistent in the 4 patient cohorts (occurring in approximately 0.4% of patients across cohorts). Overall, a total of 29 events of eosinophilia were reported in 19 patients. Ten of these patients (all from India) had at least 4 years of perampanel exposure and none had a history of asthma or allergies; in 2 of these patients, eosinophilia events were reported during the pretreatment period. Approximately half of the events of eosinophilia were classified as possibly or probably related to the study treatment by the investigator.
| Exposure-adjusted event rate of TEAEs
| Long-term seizure outcomes in the overall population
Median percent change in all focal seizures (with and without SGS) per 28 days and 50% responder rate per year (ie, during the previous 12 months) among subsets of patients who had at least 1, 2, 3, or 4 years of perampanel exposure are shown in Figures 2A-B . Seizure improvements for patients with focal seizures were stable at all time points for each of the cohorts. The largest median percent improvement in seizure frequency was observed for SGS for patients in whom SGS were present at baseline (N = 510). The median percent reduction in SGS frequency per 28 days during the third year of perampanel treatment was 88% in the 3-year cohort and 100% during the fourth year in the 4-year cohort, with corresponding 50% responder rates being 72.1% and 78.6%, respectively ( Figures 3A-B) . Patients who had SGS at baseline also showed an improvement in the frequency of all seizures (focal and SGS combined), with median percent reductions reaching 46.7%, 57.1%, 61.8%, and 68.9% for patients with at least 1, 2, 3, or 4 years of perampanel exposure, respectively, and corresponding 50% responder rates of 47.4%, 54.4%, 59.5%, and 64.3%, respectively.
A total of 129/1217 patients in the ITT Analysis Set recorded at least 1 SGS during perampanel treatment but did not have SGS during the 6-week pre-perampanel baseline. This also included 24 patients who did not report a history of SGS prior to the study or an SGS during the 6-week pre-perampanel baseline, but had SGS during perampanel treatment. Because exclusion of these patients from the initial analysis could have biased the assessment of overall changes in SGS frequency, an additional analysis of SGS was conducted in the pooled population of patients who had SGS during either baseline or perampanel treatment. Median percent reductions in SGS frequency per 28 days for this pooled population reached 52.4%, 83.5%, 88.7%, and 100% for patients with at least 1, 2, 3, or 4 years of perampanel exposure, respectively, with corresponding 50% responder rates of 52.0%, 54.9%, 55.2%, and 51.2%, respectively.
Improvements in seizure frequency during the entire perampanel treatment period were recorded equally in patients who remained on the same concomitant AEDs from baseline to the end of treatment (median percent reduction in seizure frequency per 28 days: 37.9% and 70.0% for all focal seizures and SGS, respectively), and in those patients who were given additional AED(s) (median percent reduction in seizure frequency per 28 days: 37.4% and 56.3% for all focal seizures and SGS, respectively).
| Freedom from all focal seizures and SGS
Seizure-free rates per year (ie, during the previous 12 months) for each cohort are shown in Figures 4A-B for all focal seizures and for SGS. For the 78 patients who had at least 4 years of perampanel exposure, no patients attained seizure freedom during the first year of perampanel treatment, but 10 patients (12.8%) became free from focal seizures during the fourth year of perampanel treatment ( Figure 4A ). Many patients who had SGS at baseline also become free of SGS during treatment: 17.0% (66/388) of patients who had at least 1 year of perampanel exposure attained freedom from SGS and 53.6% (15/28) of patients who had at least 4 years of perampanel exposure attained freedom from SGS in the fourth year ( Figure 4B ).
| Long-term seizure outcomes including early dropouts
Median percent reductions in all focal seizures were 42.7%, 48.6%, 50.8%, and 51.5% during the first, second, third, and fourth years of perampanel exposure, respectively, for patients who had at least 1 year of perampanel exposure. Median percent reduction in SGS were 65.0%, 79.1%,
| DISCUSSION
The results from the present study show that long-term adjunctive treatment with perampanel for up to 4 years did not raise new safety/tolerability signals and was associated with a sustained or increased improvement in seizure control. Although the number of patients remaining in the study decreased in each yearly cohort, this was not due to increased AE incidence over time, but administrative reasons (ie, termination of the study). Retention on treatment for patients with 3 or 4 years of potential exposure was not as high as that reported after 1 or 2 years 6,7 ; however, rates were similar to those reported in studies of other AEDs that evaluated retention on treatment for 2 or more years. 8, 9 The proportion of patients with at least 1 TEAE was similar across the 4 yearly cohorts, with dizziness, somnolence, and headache being most commonly reported, consistent with findings from the short-term, double-blind, phase III studies. 10 Some of the reported increases in body weight could be a result of adolescents maturing. A previous study in adolescent patients with focal seizures showed that the mean change in weight percentile increased slightly from baseline (46.1%) to end of treatment (48.0%) following treatment with adjunctive perampanel (≤12 mg/day) but F I G U R E 2 Seizure outcomes for all focal seizures from first exposure to perampanel by treatment duration cohorts: A, Yearly median percent reduction in seizure frequency per 28 days and B, 50% responder rates (ITT Analysis Set). Perampanel treatment duration starts from the first perampanel dose in the double-blind or OLEx study until the last perampanel dose in the OLEx, except for patients with a gap in perampanel exposure during the transition from the double-blind to the OLEx study of >14 days for whom the perampanel treatment duration is the OLEx exposure. Seizure reductions and responder rates at each time point correspond with the previous 12 months for each cohort. ITT, intent-to-treat; OLEx, open-label extension decreased slightly following treatment with placebo (49.9% to 49.1%) 11 ; however, as the average weight change observed in adolescents receiving perampanel was consistent with that expected for the general adolescent population, this change can be attributed to normal adolescent growth.
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Irritability was the only psychiatric TEAE that occurred in >10% of patients in the Safety Analysis Set, with an incidence ranging from 13.9% to 15.1% across the 4 yearly cohorts. However, <2% of patients discontinued due to irritability over the entire study period. The incidence of irritability reported here is similar to another recent audit, 13 however, it should be noted that other neuropsychiatric complications may have occurred during initial dose titration in the blinded-treatment phase, prior to the OLEx study conversions. 13, 14 There is also evidence suggesting that behavioral/neuropsychiatric TEAEs can be dose-related to perampanel. 15 Therefore, patients should be monitored for these symptoms, particularly during titration. 14 A total of 231 patients discontinued due to any TEAE over the entire study period, with dizziness (4.1%), irritability (1.2%), and fatigue (1.1%) being the most common TEAEs reported. Aggression and convulsion were the most common SAEs leading to discontinuation, and they occurred in <1% of treated patients. (n = 78) compared with Years 1 (n = 894), 2 (n = 681), and 3 (n = 436). As is the case for other AEDs, the prescribing information for perampanel contains a warning on suicidal behavior and ideation. 1,2 The incidence of suicidal ideation and attempt was <1% each for the total Safety Analysis Set. AEs that were reported in the 3-and 4-year cohorts were similar to those described in previous analyses after 2 years of exposure, 7 indicating that the long-term safety/ tolerability profile of perampanel is consistent with that reported in the short-term, double-blind, phase III studies.
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The exposure-adjusted event rate of TEAEs for patients with at least 1, 2, 3, or 4 years of perampanel exposure showed that dizziness was the most prevalent TEAE. This analysis also showed that TEAEs of clinical interest, such as neuropsychiatric disorders and abnormal weight gain, were stable across all patient cohorts. For the patients included in the 3-and 4-year cohorts, the median percent reduction in the frequency of all focal seizures per 28 days was as high as 62% and 71%, respectively, and for each of the study cohorts there was no trend for seizure control to decrease with increasing duration of follow-up. The improvement was especially prominent for SGS in patients who had this seizure type at baseline. Although there were also patients who had SGS during perampanel treatment but not during baseline, a pooled analysis of all patients with SGS at any time during the study confirmed a comparable degree of improvement in SGS frequency during long-term follow-up. In this difficult-to-treat population, with over one-third of patients receiving 3 concomitant AEDs, the ultimate goal of achieving seizure freedom is often elusive. However, up to 12.8% of patients with at least 4 years of perampanel exposure were free from all focal seizures, and up to 53.6% of patients with SGS at baseline were free from SGS. Interpretation of these data should recognize that there was a reduced sample size from the first to the fourth year of perampanel exposure, and the surviving cohorts have a selection bias, in that only the patients doing well remain on treatment. Nonetheless, as shown in Table 1 , less than 15% of patients in any of the study cohorts discontinued treatment because of perceived inadequate therapeutic effect.
To account for this potential bias, an additional sensitivity analysis was performed for median percent reduction in seizure frequency per 28 days, which included all patients who withdrew from the study at all time points. In this analysis, median percent reductions in the frequency of all focal seizures and SGS were maintained across the 4-year follow-up period.
As with all long-term follow-up studies, interpretation of our findings should take into account the uncontrolled nature of the study and the influence of possible confounders, including changes in background AED therapy. However, observed improvements in seizure frequency were similar in patients who remained on the same AEDs throughout the study as compared with those in whom other AEDs were added during follow-up, signifying the refractoriness of this patient cohort.
In conclusion, this study confirms previous observations from 6-month and 2-year follow-up periods, 6, 7 showing the retention of safety/tolerability and efficacy of adjunctive perampanel in patients with focal seizures, with or without SGS, aged ≥12 years treated for up to 4 years, with the most substantial improvement in seizure control observed for SGS for patients who had this seizure type at baseline.
